Literature DB >> 9485303

Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3.

H Ling1, A Boodhoo, B Hazes, M D Cummings, G D Armstrong, J L Brunton, R J Read.   

Abstract

Shiga-like toxin I (SLT-I) is a virulence factor of Escherichia coli strains that cause disease in humans. Like other members of the Shiga toxin family, it consists of an enzymatic (A) subunit and five copies of a binding subunit (the B-pentamer). The B-pentamer binds to a specific glycolipid, globotriaosylceramide (Gb3), on the surface of target cells and thereby plays a crucial role in the entry of the toxin. Here we present the crystal structure at 2.8 A resolution of the SLT-I B-pentamer complexed with an analogue of the Gb3 trisaccharide. The structure reveals a surprising density of binding sites, with three trisaccharide molecules bound to each B-subunit monomer of 69 residues. All 15 trisaccharides bind to one side of the B-pentamer, providing further evidence that this side faces the cell membrane. The structural model is consistent with data from site-directed mutagenesis and binding of carbohydrate analogues, and allows the rational design of therapeutic Gb3 analogues that block the attachment of toxin to cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485303     DOI: 10.1021/bi971806n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  127 in total

1.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

2.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

3.  Identification and characterization of a new variant of Shiga toxin 1 in Escherichia coli ONT:H19 of bovine origin.

Authors:  Christine Bürk; Richard Dietrich; Gabriele Açar; Maximilian Moravek; Michael Bülte; Erwin Märtlbauer
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Crystal structures of a group II chaperonin reveal the open and closed states associated with the protein folding cycle.

Authors:  Jose H Pereira; Corie Y Ralston; Nicholai R Douglas; Daniel Meyer; Kelly M Knee; Daniel R Goulet; Jonathan A King; Judith Frydman; Paul D Adams
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

Review 5.  Revitalizing membrane rafts: new tools and insights.

Authors:  Kai Simons; Mathias J Gerl
Journal:  Nat Rev Mol Cell Biol       Date:  2010-10       Impact factor: 94.444

6.  Change in conformation with reduction of alpha-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1.

Authors:  Maurizio Brigotti; Domenica Carnicelli; Valentina Arfilli; Laura Rocchi; Francesca Ricci; Pasqualepaolo Pagliaro; Pier Luigi Tazzari; Antonio González Vara; Matteo Amelia; Francesco Manoli; Sandra Monti
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

7.  Influence of Coulombic repulsion on the dissociation pathways and energetics of multiprotein complexes in the gas phase.

Authors:  Igor Sinelnikov; Elena N Kitova; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2007-01-03       Impact factor: 3.109

8.  Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid.

Authors:  Amit Joshi; Arundhati Saraph; Vincent Poon; Jeremy Mogridge; Ravi S Kane
Journal:  Bioconjug Chem       Date:  2006 Sep-Oct       Impact factor: 4.774

9.  The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.

Authors:  Michael J Smith; Humberto M Carvalho; Angela R Melton-Celsa; Alison D O'Brien
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

10.  Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides.

Authors:  Murugesapillai Mylvaganam; Henrik C Hansen; Beth Binnington; Göran Magnusson; Per-Georg Nyholm; Clifford A Lingwood
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.